Intelligence · Clinical Development
Pipeline search results
Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
bendamustine
Teva Pharma GmbH
Multiple Myeloma
1 trial -
cemsidomide
C4 Therapeutics
Multiple Myeloma
2 trials -
clarithromycin
BRIGHT MINDS BIOSCIENCES INC.
Relapse/Refractory Multiple Myeloma
1 trial -
ΕΑΕ-2018/ΜΜ03
Takeda
Multiple Myeloma
1 trial -
18F-FDG
The First People's Hospital of Lianyungang
Multiple Myeloma and Malignant Plasma Cell Neoplasms
1 trial -
ACTR087
Cogent Biosciences
Multiple Myeloma
1 trial -
AEVI-007
Avalo Therapeutics
Multiple Myeloma
1 trial -
ALLO-715
Allogene Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial -
Anti-BCMA CAR-T cells
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
BCMA/CD19 Dual-Target CAR-T
Xijing Hospital
Multiple Myeloma
1 trial -
C-4-29 Cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma in Relapse
1 trial -
CAR-BCMA T cells
The First People's Hospital of Lianyungang
Refractory or Relapsed Multiple Myeloma
1 trial -
CAR-T
The Third Affiliated Hospital of Southern Medical University
Multiple Myeloma
1 trial -
CAR-T Re-treatment
Nanjing Legend Biotech Co.
Multiple Myeloma
1 trial -
CB-011
Caribou Biosciences
Relapsed/Refractory Multiple Myeloma
1 trial -
CD56-Enriched Donor Lymphocyte Infusion
Teva Pharma GmbH
Multiple Myeloma
1 trial -
CID-103
CASI Pharmaceuticals
Multiple Myeloma
1 trial -
CLN-619
Cullinan Therapeutics
Multiple Myeloma
1 trial -
CM336 (BCMA/CD3 bispecific antibody)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed Refractory Multiple Myeloma (RRMM)
1 trial -
CTX120
S.A.
Multiple Myeloma
1 trial -
Cemsidomide
C4 Therapeutics
Multiple Myeloma (MM)
1 trial -
Ciforadenant
Corvus Pharmaceuticals
Multiple Myeloma
1 trial -
Descartes-08
Cartesian Therapeutics
Multiple Myeloma
1 trial -
Descartes-15
Cartesian Therapeutics
Refractory Multiple Myeloma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.